Post-earnings recap
Reported
Thu, Nov 3, 2022
Est. EPS
—
Est. revenue
—
Implied move
—
EPS beat rate
75%
—
Est. EPS
—
Est. Rev
—
Impl. Move
—
Denali Therapeutics reported a loss per share of $0.84, which was below expectations. The stock reacted slightly down by 0.33%, indicating a muted response from investors. The lack of revenue data and management commentary leaves uncertainty about the company's current performance and future outlook.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.84 | N/A | -0.96% |
| Revenue | N/A | N/A | N/A |
No transcript is on record, and the analysis is based on numerical results only.